ARCUTIS BIOTHERAPEUTICS, INC. Payments of Loan Costs
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) reported Payments of Loan Costs of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfLoanCosts · last filed 2022-02-22
- ARCUTIS BIOTHERAPEUTICS, INC. payments of loan costs for fiscal 2021 was $0.00.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of loan costs for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- ARCUTIS BIOTHERAPEUTICS, INC. payments of loan costs for fiscal 2019 was $1.40M.
| Period end | Payments of Loan Costs 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-22 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-22 |
| 2019-12-31 | $1.40M 10-K · filed 2022-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |